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Summary Sublines from the small cell lung cancer (SCLC) cell lines U1285 and U1690, denoted U1285-100,
U1285-250, U1690-40 and U1690-150, were adapted to grow in the continuous presence of 100, 250, 40 and
150 ng ml-' doxorubicin (Dox), respectively. The Dox resistance was accompanied by cross-resistance to
vincristine (Vcr), Vp-16 and for U1285-100 also to cisplatinum. Sublines of U1690-40 and U1285-100, cultured
in absence of Dox for 4 months were only partially reversed with respect to Dox resistance. Neither the
parental nor the most Dox resistance sublines had detectable levels of mdr RNA but a small fraction of cells
in all cell lines stained weakly positive for P-glycoprotein (P-gp). Verapamil (Ver) at 5 gsM reversed the Dox
resistance completely and partly in the U1690 and U1285 sublines, respectively, but did not increase the
cellular accumulation of Dox. The cytoplasmic free Ca2" concentration (Ca2+i) was close to 100 nm in both
parental cell lines but elevated in the U1285-100 and U1690-40 sublines by 21 and 44%, respectively, and in
U1285-250 and U1690-150 by 51 and 91%, respectively. The partly reverted sublines still showed significant
but smaller elevations in Ca2+i of 10-30%. Ver was without acute or long term effects of Ca2+i in the
U1285-100 and U1690-40 sublines. Selection for Dox resistance in SCLC may thus result in atypical
multidrug-resistance characterised by absence of P-gp overexpression and atypical cross-resistance. Although
Ver did not seem to affect Dox accumulation it may still work as a resistance modulator. There may be a role
for increased Ca2+i in drug resistance in SCLC cells, but resistance reversal by Ver seems unrelated also to
changes in Ca2+i.
Acquired cytotoxic drug resistance is often extended also to
drugs not included in the treatment regimen and the most
consistent finding in vitro in such multidrug-resistance
(MDR) is resistance to anthracyclines, vinca alkaloids and
epipodophyllotoxins with a decreased drug accumulation
compared to the sensistive cells (Beck, 1987; Bradley et al.,
1988). In vivo (Goldstein et al., 1989) as well as in vitro
(Beck, 1987; Bradley et al., 1988) the MDR phenotype is
often characterised by expression of the 170 kDa membrane
P-glycoprotein (P-gp) encoded by the mdr gene (Ueda et al.,
1987). Several lines of evidence indicate that this protein
mediates an energy dependent extrusion of various cytotoxic
drugs (Beck, 1987; Bradley et al., 1988; Horio et al., 1988).
Several well known pharmacological agents have been
shown to reverse MDR in vitro (Ford & Hait, 1990). One of
the most studied of these resistance modulators is the calcium
channel blocker verapamil (Ver), which modulates acquired
as well as intrinsic drug resistance of various cell types
(Simpson, 1985). The mechanism for resistance reversal by
Ver is still not completely understood although it has been
found that Ver may compete with cytotoxic drugs for bind-
ing to the P-gp, resulting in a decrease in drug efflux and
thus enhanced cytotoxicity (Safa et al., 1987; Yusa & Tsuruo,
1989).
Transmembrane transport as well as many other cell func-
tions are known to be regulated by intracellular signals such
as, e.g. changes in the cytoplasmic free Ca2l concentration
(Ca2+i; Rasmussen & Barrett, 1984). Based on findings of
increased calcium content of MDR cells (Tsuruo et al., 1984)
and resistance reversal by the calcium channel blocker Ver, it
has been speculated that Ca2+i may have role in cytotoxic
drug resistance and that the sensitising effect of Ver could be
due to a decrease in Ca2+i (Beck, 1987).
In the present study some of these hypotheses were
evaluted in two established human small cell lung cancer
(SCLC) cell lines. We investigated whether development of
resistance to doxorubicin (Dox) also conferred resistance to
other cytotoxic drugs and was accompanied by increased
expression of P-gp and changes in drug accumulation. The
possible role of Ca2+i in drug resistance was evaluated by
quin2 measurements in sublines showing varying degrees of
drug resistance. Furthermore, the possible potentiating effect
of Ver on Dox cytotoxicity was evaluated and correlated to
acute and long term changes in Ca2+i.
Materials and methods
Cell lines and culture
The human U1285 and U1690 SCLC were established as
described previously (Bergh et al., 1982; Bergh et al.,
1985a). Both lines have a doubling time of about 3 days. By
gradually increasing the Dox (Farmitalia Carlo Erba, Italy)
concentration in the culture medium, sublines of U-1285
and U-1690, denoted U1285-100, U1285-250, U1690-40 and
U1690-150 were adpated to grow with similar doubling
times as the parental lines in the continuous presence of
100, 250, 40 and 150 ng ml Dox, respectively. Sublines
from U1285-100 and U1690-40, denoted U1285-(100) and
U1690-(40), respectively, were cultured in absence of Dox
for 4 months prior to inclusion in the experiments and will
be referred to as revertant cell lines. All cell lines were
grown in RPMI 1640 medium (Flow Laboratories, Herts,
England) containing 10% foetal calf serum (FSC; Flow)
and antibiotics and were refed twice weakly. The cultures
were incubated at 37°C in an atmosphere containing 5% CO2
and 95% air. In control experiments for expression of P-gp,
mdrl RNA and drug accumulation the parental T-ALL cell
line LO and its vincristine (Vcr) resistant subline L100, kindly
provided by Dr L. Slater, Department of Medicine, Univer-
sity of California, Irvine, CA (Slater et al., 1986) as well as
the chronic myelocytic leukaemia cell line K562 (Lozzio &
Lozzio, 1975) and its subline K562/Vcr, adapted to growth in
presence of 30 mm Vcr, were used. The LIOO subline is
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approximately 160-fold Vcr resistant, shows cross-resistance
to Dox and Vp-16, expresses P-gp and is modulated by Ver
(Nygren & Larsson, 1991). The K562/Vcr subline is
approximately 250-fold Vcr resistant and shares the other
characteristics with the LIOO subline (Nygren & Larsson,
unpublished data).
For investigation of the cytotoxic drug sensitivity, 25,000
cells in 190 il culture medium were seeded into each well of
flat bottomed 96 well microtiter culture plates (Nunc, Ros-
kilde, Denmark). The indicated concentrations of Dox, Vcr
(Sigma Chemical Co., St. Louis, MO), cisplatinum (Cisp;
Sigma) or Vp-16 (Bristol-Myers, Solna, Sweden), all dis-
solved in phosphate buffered saline (PBS), were then added
to triplicate wells. For evaluation of a possible sensitising
effect of Ver on Dox sensitivity and of the glutathione
depletor buthionine sulfoximine (BSO; Sigma; Meister, 1988)
on Cisp sensitivity, 51M Ver (in dimethyl sulfoxide/PBS;
Sigma) or 1-10tLM BSO (in PBS) was addedjust prior to the
cytotoxic drug. The volume of each added drug was always
10 l giving a final maximal dimethyl sulfoxide concentration
of0.1%, which did not affect cell growth. The cells were then
cultured for 72 h under the conditions described above. No
medium change was done during the culture period.
Measurement ofcell survival
Cell survival after culture was estimated by using the
fluorogenic substrate fluorescein diacetate (FDA; Sigma)
which rapidly enters intact cells where it is hydrolysed to its
fluorescent derivative fluorescein (Rotman & Papermaster,
1966). The details of this technique have recently been de-
scribed (Larsson & Nygren, 1990). Briefly, after culture the
plates were centrifuged (100g, 5 min), the medium removed
by flicking the plate, and the wells washed once with 200lil
of the buffer described below. To each well was then added
200pl of assay buffer containing 0.5 mM Mg2 , 1,25 mM
Ca2", 3 mM glucose, 10 mM Hepes (pH 7.4) and physio-
logically balanced in other cations and with Cl- as the sole
anion and with 10l"gml-l FDA. The plates were then
incubated for 60min at 37°C after which the fluorescence
from each well was read in a Fluoroscan II microfluorometer
(Flow) with filters set at 485 and 538 nm for excitation and
emission, respectively. The fluorometer was blanked against
wells containing assay medium with dye. Each plate was read
in about 1 min and the fluorescence data was then imported
to a Macintosh SE computer for statistical and graphical
processing.
Cell survival after culture is expressed as survival index
(SI) defined as FDA fluorescence for treated wells/FDA
fluorescence for untreated control wells expressed as per cent.
IC50 was defined as the cytotoxic drug concentration resulting
in a SI of 50% ofcontrol. Resistance factor (RF) was defined
as IC50 for the subline/IC50 for the parental line.
Immunohistochemicalstainingfor P-gtycoprotein
P-gp staining was performed using the monoclonal anti-P-gp
antibody JSB-1 (Sanbio, Uden, The Netherlands; Scheper et
al., 1988) with the technique described previously (Bergh et
al., 1985b). Frozen sections (4-6tM) of human adrenal cor-
tex and cytocentrifuge preparations of MDR L100 and
K562/Vcr cells were used as positive controls whereas sensi-
tive LO and K562 cells and preparations stained with the
above technique, but without primary antibody served as
negative controls. The specimens were incubated with the
JSB-1 antibody diluted 1/30 in PBS for 60min, followed by
washing and application of a biotinylated rabbit-anti-mouse
complex (Vector Laboratories Inc., Burlingame, CA) and
then a avidin-biotinylated horseradish peroxidase complex
(Vector Laboratories). The coverslips were then developed in
0.02% 3-amino-9 ethycarbazole supplemented with 0.002%
H202-
The specimens were counterstained with Mayer's hematoxy-
lin, mounted and judged -, +, + + or + + + by light
microscopy. In separate control experiments the monoclonal
P-gp antibody C219 (Centocor, Malvern, PA; Kartner et al.,
1985) was used instead of JSB-1.
Measurement ofmdrl RNA
Measurement of mdrl mRNA was performed by hybridisa- tion in solution as described (Durnam et al., 1983; Mathews
et al., 1986; Steen et al., 1990) with K562 and K562/Vcr as
controls. Nucleic acids extracts were prepared (Durnam et
al., 1983) and aliquots were taken for determination of DNA
content by Hoechst fluorometry (Labarca et al., 1980). Plas-
mid pGem-4 (Promega Corporation, Madison, WI) carrying
1383 basepairs of the mdrl cDNA sequence (pHDR5A) was
kindly provided by Drs M. Gottesman and I. Pastan, NCI,
Bethesda, MD (Ueda et al., 1987). A 393 basepair long
sequence was subcloned into a new plasmid (pGem-3Zf (+);
Promega). A 403 nucleotides long antisense probe was
generated by transcription of Stu I (New England Biolabs,
Beverly, USA) cleaved pHDRSA with SP6 RNA polymerase
(Promega) in the presence of r35]UTP (>37 x 106
MBqmmol'l; Amersham International, Amersham, Eng- land). A 439 nucleotides long unlabelled sense RNA (comple-
mentary to the labelled antisense probe) was transcribed by Sp6 RNA polymerase from EcoRI (New England Biolabs) cleaved pGem-3Zf (+). The concentration of the unlabelled
RNA was determined spectrophotometrically at 260 nm.
Aliquots of the extracts or unlabelled sense RNA were
adjusted to 20ftl with 0.2 x SET (1 x SET is 1% sodium
dodecyl sulfate, 10 mM ethylenediaminetetraacetic acid
(EDTA) and 20 mM Tris-HCl, pH 7.5) and mixed with
30,000 counts per min (c.p.m.) ofantisense probe dissolved in
20 ltl hybridisation solution (0.6 M NaCl, 4mM EDTA,
7.5 mM dithiothreitol, 25% deionised recrystallised for-
mamide and 20 mM Tris-HCl, pH 7.5) and incubated for 18 h
at 68°C. Subsequently, the samples were treated with 1 ml of
an RNase solution of 40gg ml-' RNase A (Sigma),
2 ig ml-' RNase Tl (Sigma), 100g.ug ml-' salmon sperm
DNA (Sigma), 0.3M NaCl, 2mM EDTA, 1OmM Tris-HCl
(pH 7.5) and incubated for 45 min at 37°C. After addition of
100Id 100% trichloroacetic acid, samples were kept on ice
for 30 min and the RNase resistant precipitates were col-
lected on Whatman GF/C filters (Whatman International,
Maidstone, England). After addition of 4 ml Insta-gel scintil-
lation liquid (Packard Instrument Company, Downers Grove,
ILL) the radioactivity was determined in a liquid scintillation
counter (Packard).
The quantities of mdrl RNa in the extracts were deter-
mined by comparison with a standard curve, generated by
hybridisation with increasing amounts of the unlabelled sense
(Steen et al., 1990). Samples classified as positive for mdrl
RNA show at least twice the background radioactivity and a
proportional increase in radioactivity with increasing
amounts of added extracts. The results are presented as
c.p.m. with background subtracted for three dilutions ofeach
extract. Based on the standard curve, a molecular weight of
sense RNA of 1.49 x 105, c.p.m. IAg'- DNA values for each
extract and the assumption of a DNA content of 6 pgcell-',
the number of mdrl RNa copies/cell may be calculated. The
detection limit in a sample containing 30fig DNA is
7.5 x I05 copies of RNA which corresponds to 0.15 RNA
copies cell-'.
Measurement ofcellular doxorubicin accumulation
The parental and most resistant sublines were compared with
respect to Dox accumulation in absence and presence of Ver.
The cells were incubated at 37°C for 1 h at a density of
1.5 x 106cells ml-' in RPMI 1640 medium supplemented with
10% newborn calf serum (Gibco, Paisley, Scotland) and
containing 1 tiM Dox and with or without 5lM Ver. The
incubation was stopped by mixing 1.5 ml of the incubate
with 5 ml ice cold PBS. After two washes in ice cold PBS the
cell pellets were kept in - 20°C until analysis.
Cellular concentrations of Dox were determined by high-
performance liquid chromatography as described (Baurin etDRUG RESISTANCE IN SMALL CELL LUNG CANCER CELL LINES 1013
al., 1978). Briefly, after sonication ofeach cell pellet in 0.5 ml
PBS a 0.2 ml aliquit was added to 0.2 ml 0.1 M borate buffer
(pH 9.8) containing 1 gM daunorubicin as internal standard.
Extraction was made by addition of 1.8 ml chloroform/
methanol (4:1 by volume) after which the drugs were
separated on a Lichosorb Si-60 column (Hibar; Merck,
Darmstadt, Germany) and eluted with a mixture of
chloroform, methanol, glacial acetic acid and 0.3 mM MgCl2
(720:210:40:30 by volume) at a flow rate of 1.5mlmin-'.
The drugs were then quantified by fluorometry at 480 and
560 nm for excitation and emission wavelengths, respectively.
The protein content in the dissolved cell pellets was deter-
mined by the method described by Lowry (Lowry et al.,
1951) and the cellular accumulation of Dox is expressed as
nmol Dox mg-' protein.
Measurement ofthe cytoplasmicfree Ca" concentration
Fluorometric measurements of Ca2"i were performed as de-
scribed previously (Nygren et al., 1988). Briefly, 5 x 106
quin2 (Sigma; Tsien et al., 1982) loaded cells were suspended
in 1.3 ml of the buffer used for cell survival measurements
and incubated with constant stirring at 37°C in a 1 cm
cuvette of a Perkin-Elmer LS5 spectrofluorometer with
excitation and emission wavelengths set at 339 and 492 nm,
respectively. Ver was added from a 100-fold concentrated
stock solution in DMSO/buffer. In the measurement of the
long term effect of Ver on Ca2"i, 5 tLM Ver was present also
in the physiological buffer used for washing and assay. The
addition of vehicle was without effect on quin2 fluorescence.
Calibration for calculation of Ca2"i was then performed as
described (Nygren et al., 1988). Extracellular quin2 never
exceeded 7% of Fmax as judged by the fall of fluorescence
signal after addition of 3 mM EGTA and was similar in all
cell lines. The increase in fluorescence upon addition of the
intracellular heavy metal chelator TPEN (Calbiochem, La
Jolla, CA; Arslan et al., 1985) corresponds to a rise in Ca21i
of 30-40 nM in all cell lines, indicating no significant
differences in quenching heavy metal content.
Student's paired t-test was used for statistical comparisons.
Results
Cytotoxic drug sensitivity and effects ofresistance modulators
The IC50 values for Dox were 0.4 and 0.21gml-mI for the
parental U1690 and U1285 cell lines, respectively (Table I).
The resistant sublines U1690-40 and U1690-150 were approxi-
mately 6 and 7-fold resistant to Dox whereas the revertant
subline U1690-(40) retained most of its Dox resistance with a
RF of 4. The corresponding values for U1285-100 and
U1285-250 were 18 and 16, respectively, whereas the rever-
tant U1285-(100) showed a RF of 8. The sublines also
developed cross-resistance to Vcr, which for the U1690 sub-
lines was of even higher magnitude than for Dox with RFs of
40 and 246 for U1690-40 and U1690-150, respectively. Again
the U1690-(40) revertant subline retained much of its original
resistance with a RF of 34. The corresponding values for
U1285-100 and U1285-250 were 5 and 17, respectively. The
revertant U1285-(100) cells showed a paradoxical 2-fold in-
crease in Vcr sensitivity compared to the parental cell line.
The U1690-40 and U1285-100 sublines were also cross-
resistant to Vp-16 with RFs of 16 and 8, respectively. To
check for cross-resistant to a cytotoxic agent not included in
the typical MDR phenotype we also investigated two sub-
lines for Cisp sensitivity. U1690-40 and U1285-100 were
found 1.4 and 4-fold resistant compared to the parental lines.
Ver at 5 JAM reversed the Dox resistance completely in the
U1690 sublines and partly in the U1285 sublines (Table I).
BSO at 1-1 LM, depending on the sensitivity of the cell lines
to BSO alone, increased the Cisp sensitivity 1.3-5-fold in
parental and resistant cells.
The U1690 sublines showed minor collateral sensitivity to
both Ver and BSO with normalisation to the parental
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phenotype in the revertant subline (Figure 1). In the U1285
series of cell lines there was no evidence for collateral sen-
sitivity or cross-resistance to these modulators (Figure 2).
Expression ofP-glycoprotein
As expected adrenal cortex stained strongly positive for P-gp
(Table II). The parental LO and K562 cells were found
negative whereas the majority of the MDR L100 and K562/
Vcr cells stained positive, although weaker than adrenal
cortical cells. Both the U1690 and U1285 cell lines as well as
their drug resistant sublines showed faint membrane staining
in a small proportion (<15%) of the cells. Qualitatively
similar results were obtained in control expenrments using the
monoclonal antibody C219 (not shown). Furthermore,
Western blotting confirmed expression of a protein reactive
with the C219 antibody in L100 cells whereas no such pro-
tein was found in the LO cells or any of the SCLC cell lines
(not shown).
Expression ofmdrl RNA
Data for hybridisation between labelled RNA probe and
unlabelled sense RNA (standard curve) or nucleic acid ex-
tract from K562/Vcr are shown in Figure 3a. There is a
proportional increase in radioactivity with increasing
amounts of added sense RNA or extract. The c.p.m. for
K562/Vcr corresponds to approximately 98 mdr1 RNA
copies/cell. For parental K562 cells as well as the parental
and most resistant SCLC sublines the c.p.m. values were just
above background and the mdr1 RNA content of these
samples was below the detection limit ofthe assay (Figure 3b).
Cellular doxorubicin accumulation
The U1690-150 and U1285-250 sublines accumulated some-
what more and less Dox, respectively, compared to their
parental cell lines (Figure 4). Presence of 5 JM Ver during
incubation did not affect the Dox accumulation in any cell
line. In control experiments using the same method, K562/
Vcr cells were found to accumulate 50% less daunorubicin
compared to the parental cells and presence of Ver during
incubation normalised this accumulation defect (not
shown).
Cytoplasmicfree Ca2" concentrations
Basal Ca2"i of U1690 cells was 100 nM and was increased to
144 and 191 nM for the U1690-40 and U1690-l50 sublines,
respectively (Figure 5a; P <0,001 vs parental cells). The
revertant subline U1690-(40) showed a Ca2"i 30nM higher
than the U1690 cells (P <0,02). The Ca2"i differences were
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Figure 1 Effects ofincreasing concentrations ofVer a, and BSO,
b, in the parental U1690 cell line and its resistant sublines. The
indicated concentrations of Ver or BSO were added in triplicate
wells at day 0 and the cultures then incubated for 72 h followed
by determination of SI as described in Materials and methods.
Mean values ± s.e. of 4-7 experiments. 0 U1690; * U1690-40;
0 U1690-150; A U1690-(40).
qualitatively similar in the U1285 series ofcell lines, although
quantitatively less with Ca2"i values of 106, 128 (P <0,01),
160 (P <0,001) and 117 nM (P <0,05) for the U1285, U1285-
100, U1285-250 and U1285-(100) cell lines, respectively
(Figure 5b).
Addition of 5 M Ver was without acute (within 3 min)
effect on Ca21i in the parental cell lines and the U1690-40
and U1285-100 sublines (Figure 6). After incubation with
5 JAM Ver for 48 h, Ca21i was slightly decreased by 13 nM in
U1285 cells whereas Ca2"i in the other cell lines was not
significantly altered.
Table II Expression of immunohistochemically detectable P-glycoproteina
Tissue/Cell type
Adrenal cortex
LO
e Staining reaction % of cells positive Region positive
+ + + 75-100 Membrane
L1OO + + 75-100 Membrane/Golgi
K562 - -
K562/Vcr + + 75-100 Membrane
U1285 + < 15 Membrane
U1285-100 + < 15 Membrane
U1285-250 + < 15 Membrane
U1285-(100) + < 15 Membrane
U1690 + < 15 Membrane
U1690-40 + < 15 Membrane
U1690-150 + < 15 Membrane
U1690-(40) + < 15 Membrane
aImmunohistochemical stainings were performed as described in Materials and
methods using the monoclonal antibody JSB-1. Intensity of staining is in
comparison to adrenal cortex which was judged as + + +. The fraction of cells
positive was determined by examination of 100 cells in each experiment. Data
from one typical experiment of 4.
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Figure 4 Dox accumulation of U1690 and U1285 cell lines and
their most resistant sublines after incubation in 1 !LM Dox for h
in absence (open bars) or presence (hatched bars) of 5gM Ver.
Mean ± s.e. for six samples.
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Figure 2 Effects of increasing concentrations of Ver a, and BSO
b, in the parental U1285 cell line and its resistant sublines. The
indicated concentrations or Ver of BSO were added in triplicate
wells at day 0 and the cultures then incubated for 72 h followed
by determination of SI as described in Materials and methods.
Mean values ± s.e. of 4-7 experiments. 0 U1285; * U1285-100;
* U1285-250; A U1285-(100).
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Figure 5 Steady state Ca2+i of U1690 and U1285 cell lines and
their resistant sublines. Ca2+i was measured fluorometrically using quin2 as described in Materials and methods. Mean ± s.e.
for 7-17 experiments, each performed in duplicates.
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Figure 3 Hybridisation between labelled mdrl RNA probe and
increasing amounts of unlabelled sense RNA (standard curve, inset) or nucleic acid extract from K562/Vcr cells a. The corre-
sponding data for the parental K562 cells as well as for the
parental and most resistant SCLC cell lines indicate mdrl RNA
levels below the detection limit of the assay b. Data from one
typical experiment. 0 K562; U1690; * U1690-150; A U1285;
A U1285-250.
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Figure 6 Ca2+i steady-state deviation from Ca21i of unexposed control cells in U1285, U1285-100, U1690 and U1690-40 cells immediately after addition of 5 M Ver (open bars) and after
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Discussion
During the last years several human cell lines have been
described showing MDR patterns deviating from the classical
one. This includes atypical cross-resistance (Beck et al., 1987;
Haber et al., 1989; Baas et al., 1990), presence of P-gp
without increased drug efflux (Deffie et al., 1988), absence of
P-gp overexpression with (McGrath & Center, 1988; Haber
et al., 1989; Reeve et al., 1990) or without (Beck, et al., 1987)
drug accumulation defects and cytotoxic drug potentiation
by Ver also in absence of P-gp (Nygren & Larsson, 1990a;
Baas et al., 1990) and dissociated from changes in cytotoxic
drug accumulation (Chang et al., 1989). An interesting
feature of these atypical MDR cell lines is that most have
been selected for resistance by exposure to increasing concen-
trations of Dox.
For SCLC, typical MDR (Morgan et al., 1989) and
atypical (Cole et al., 1989) drug resistant cell lines have been
described, the latter showing the classical MDR cross-
resistance pattern, absence of P-gp overexpression, modest
potentiation by calcium channel antagonists and lack of col-
lateral sensitivity to resistance modulators. Also the resistant
SCLC cell lines in the present investigation do no adhere to
the typical MDR phenotype. The cells were resistant to Dox,
Vcr and Vp-16, three drugs included in the typical MDR
phenotype (Ford & Hait, 1990) but for U1285-100 also to
Cisp. Furthermore, the Vcr resistance was similar (U1285
series) or considerably higher (U1690 series) than for the
selecting agent, a feature which is less common (Bradley et
al., 1988).
There was also no evidence for P-gp overexpression in the
resistant cells. This is probably not due to technical
difficulties since the P-gp overexpression associated with the
low grade (6-fold) Dox resistance of RPMI 8226/Dox6
myeloma cells (Dalton et al., 1989) was detected immuno-
histochemically (not shown) and we also found the LIOO,
K562/Vcr and adrenal cortical cells to be positive. Further-
more, the findings were confirmed by Western immunoblot-
ting using the monoclonal antibody C219 (not shown) and by
the absence of mdrl RNA. The faint immunostaining in a
minority of SCLC cells probably represents the background
level of the method. However, more important than to dis-
criminate between very low levels and complete absence of
P-gp is that no signs of P-gp overexpression in the Dox
selected sublines could be detected.
Ver reversal of cytotoxic drug resistance in classical MDR
is considered to be mediated through increased cellular drug
content, probably by inhibition of drug extrusion by P-gp
(Ford & Hait, 1990). Despite the absence of P-gp overexpres-
sion in the resistant SCLC cell lines the Dox resistance was
completely or partly reversed by Ver. Furthermore, Ver was
without effect on cellular Dox accumulation. Together the
present findings confirm the recent reports cited above on
'atypical' MDR also for SCLC cells and implicate the
presence of other mechanisms for MDR than only P-gp
mediated drug extrusion and also for Ver induced circumven-
tion of resistance.
Despite the SCLC origin of both the U1690 and U1285
cell lines and similar procedures for establishment of resistant
sublines including the selecting drug Dox, some apparent
differences in the resistance phenotypes could be noted. The
Dox resistance was thus completely reversed by Ver in the
U1690 but only partially in the U1285 sublines. The mag-
nitude of Vcr resistance was considerably higher than for
Dox in the U1690, but not in the U1285 sublines. U1690-40
and U1690-150 showed a tendency to collateral sensitivity for
Ver and BSO which was not the case for U1285-100 and
U1285-250. Furthermore, the revertant U1690-(40) and
U1285-(100) sublines were only partially reversed with
respect to Dox sensitivity, but essentially unaffected and
more than completely reversed, respectively, with respect to
Vcr sensitivity.
Together with the previous findings ofclassical (Morgan et
al., 1989) as well as atypical (Cole et al., 1989) MDR in Dox
selected SCLC cell lines these findings indicate the presence
of different pathways to the final resistant phenotype, also in
cells of the same histological type and selected for resistance
to the same cytotoxic drug. If this is true also for develop-
ment of drug resistance in vivo it may have important impli-
cations for the therapy of resistant tumours. Cytotoxic drug
treatment, its potentiation by resistance modulators and
exploitation of collateral sensitivity could not be based on,
e.g., histology, previous therapy or P-gp expression, but
rather on individual in vitro testing using techniques showing
good clinical correlations.
Based on the fact that Ca2"i is an important intracellular
messenger regulating, e.g., cell growth, secretion and trans-
port mechanisms (Rasmussen & Barrett, 1984), the initial
finding of increased Ca2" content of drug resistant compared
to sensitive cells (Tsuruo et al., 1984) as well as resistance
reversal by calcium channel antagonists and calmodulin
inhibitors (Ford & Hait, 1990), it has been speculated that
Ca2"i may be of importance in drug resistance (Beck, 1987).
A possible relationship between Ca2" and drug resistance has
also been indicated by the findings that Ca2+-ionophores
tend to induce resistance (Huet & Robert, 1988; Nygren &
Larsson, 1990b) whereas incubation under conditions known
to decrease Ca2+i has the opposite effect (Huet & Robert,
1988). However, other studies have failed to reveal a consis-
tent relationship between drug resistance and Ca2lin pairs of
sensitive and resistant cell lines (Nair et al., 1986; Vayuvegula
et al., 1988) and in experiments in which Ca2"i was
manipulated pharmacologically (Nygren & Larsson, 1990b).
Furthermore, indirect and direct measurements of Ca2"i have
failed to show any changes induced by Ver despite its
cytotoxic drug potentiation (Huet & Robert, 1988; Nygren &
Larsson, 1990a).
In the SCLC cell lines included in the present study there
was a fairly close correlation between the level of cytotoxic
drug resitance and Ca2"i. The differences are probably not
technical artifacts since the amount of extracellular quin2
was similar for all cell types and the intracellular heavy metal
chelator TPEN (Arslan et al., 1985) revealed similar amounts
of quenching metals in the different cell types. Although Dox
had no effect on resting Ca2"i in neuroblastoma cells (Oakes
et al., 1990), prolonged Dox exposure have been found to
lead to cellular Ca2+ accumulation (Keyes et al., 1987) and
inhibition of Na+/Ca2+ exchange (Caroni et al., 1981). One
could therefore speculate that the elevated Ca2+i in the
resistant SCLC cell lines is due to the direct effect of Dox
exposure. However, the revertant cell lines still showed
significantly elevated Ca21i, in parallel with at least some
retention of drug resistance. Although previous studies are
contradictory with respect to the role of Ca21i in drug resis-
tance, the present findings indicate a possible causal relation-
ship between Ca2+i and drug resistance in specific cell types
and drug resistance phenotypes.
There was no acute change in Ca2'i after Ver addition in
cells being sensitive to the potentiating effect of Ver, and long
term incubation with the calcium channel blocker did not
result in any further changes in Ca2'i. These findings cor-
roborate similar findings in cells showing intrinsic (Nygren &
Larsson, 1990a) and acquired (Huet & Roberts, 1988) drug
resistance also in cells characterised by elevated Ca2+i. It is
therefore concluded that although the exact role for Ca2+i in
cytotoxic drug resistance remains to be elucidated, the poten-
tiating effect of Ver on the effect of cytotoxic drugs is
unrelated to changes in Ca21i. Since data now accumulate
showing resistance modulation by Ver also in absence of
P-gp overexpression and drug transport changes, altenative
mechanisms for the Ver effect should be looked for.
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